ClinicalTrials.gov
ClinicalTrials.gov Menu

Redistribution of Fat and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00244803
Recruitment Status : Completed
First Posted : October 27, 2005
Last Update Posted : August 31, 2016
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
The purpose of this study is to learn whether HIV-infected patients have blood abnormalities which could lead to heart attack or stroke, and to find out what factors may contribute to these abnormalities.

Condition or disease
Human Immunodeficiency Virus

Detailed Description:

This research is being done to learn whether HIV-infected patients have abnormalities in their blood vessels that could eventually lead to heart attack or stroke (atherosclerosis), in how fat is distributed in their body and in how their body handles fat and sugars. If there are abnormalities, this study will also try to find out what factors may contribute to those abnormalitites.

People who participated in FRAM 1 may join FRAM 2.


Study Type : Observational
Actual Enrollment : 101 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Redistribution and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)
Study Start Date : January 2005
Actual Primary Completion Date : May 2007
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Group/Cohort
HIV Positive FRAM 1 Participant




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
men or women 18-65 years old, previous FRAM 1 participant, HIV positive
Criteria

Inclusion Criteria:

  • 18-65 years old
  • previous FRAM 1 participant
  • HIV positive

Exclusion Criteria:

  • Artificial knee or hip replacement or Harrington rod
  • Metal objects in the body.Pregnancy
  • Breastfeeding or less than 3 months after breastfeeding
  • Weight more than 300 pound
  • On insulin, pancreatic enzymes, or thioridazine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00244803


Locations
United States, Maryland
Johns Hopkins University, The Clinical Trials Unit
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
Johns Hopkins University
National Institutes of Health (NIH)
Investigators
Principal Investigator: Joseph Cofrancesco Jr., M.D. Johns Hopkins University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00244803     History of Changes
Other Study ID Numbers: 03-07-02-01
First Posted: October 27, 2005    Key Record Dates
Last Update Posted: August 31, 2016
Last Verified: August 2016

Keywords provided by Johns Hopkins University:
Human Immunodeficiency Virus
FRAM 1

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immune System Diseases
Slow Virus Diseases